Correction: Empagliflozin versus Sitagliptin as add-on dual therapy in Egyptian patients with type 2 diabetes inadequately controlled with Metformin: a 12-week randomized, open-label, parallel-group trial

Haitham G. Zakaraia1*, Heba F. Salem2, Mostafa A. A. Mostafa3, Ahmed M. Ali4 and Hoda M. Rabea5

The authors would like to inform the readership that this article, published in November 2023, presents the first part of our research on the use of DPP-4 and SGLT-2 inhibitors in Egyptian diabetic patients. Part two of this research, which studies the prolonged impact of the medications discussed in this paper, can be found in [1].

Published online: 29 March 2024